Channel therapeutics highlights differences between nav1.7 and nav1.8 in light of recent clinical data on suzetrigine

Freehold, n.j., dec. 20, 2024 (globe newswire) -- channel therapeutics corporation, (“channel” or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding vertex pharmaceutical's recently announced phase 2 data of suzetrigine, an investigational, oral, highly selective nav1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.
CHRO Ratings Summary
CHRO Quant Ranking